iGMDRD119

Canonical SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC

InChI: InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3

InChI Key: CBPNZQVSJQDFBE-UHFFFAOYSA-N

Loading, please wait...
Standard Name
CHEMBL
Pubchem CID
Drug Status
Drug Type
Standard NameTemsirolimus
CHEMBLCHEMBL1201182
Pubchem CID148191
Drug StatusAlone
Drug TypeSmall Molecule

Drug Targets:

MTOR

Drug Pathways:

PI3K/MTOR signaling

Drug-model tissue-cancer distribution: Bubble Plot

BLOOtissue: BLOO cancer: BLOOD model num: 0BLOODtissue: BLOOD cancer: undefined model num: 1undefinetissue: undefine cancer: undefined model num: 0undefinedtissue: undefined cancer: PANCAN model num: 22LUNtissue: LUN cancer: LUNG model num: 0LUNGtissue: LUNG cancer: undefined model num: 1LUNGtissue: LUNG cancer: Lung Adenocarcinoma (LUAD) model num: 1BOWEtissue: BOWE cancer: BOWEL model num: 0BOWELtissue: BOWEL cancer: undefined model num: 1BREAStissue: BREAS cancer: BREAST model num: 0BREASTtissue: BREAST cancer: undefined model num: 1BREASTtissue: BREAST cancer: Invasive Breast Carcinoma (BRCA) model num: 2BREASTtissue: BREAST cancer: Breast Carcinoma model num: 2SKItissue: SKI cancer: SKIN model num: 0SKINtissue: SKIN cancer: undefined model num: 1SKINtissue: SKIN cancer: Cutaneous Melanoma (SKCM) model num: 1UTERUtissue: UTERU cancer: UTERUS model num: 0UTERUStissue: UTERUS cancer: undefined model num: 1UTERUStissue: UTERUS cancer: Endometrial Carcinoma (UCEC) model num: 9LYMPtissue: LYMP cancer: LYMPH model num: 0LYMPHtissue: LYMPH cancer: Diffuse Large B-Cell Lymphoma (DLBCL) model num: 1KIDNEtissue: KIDNE cancer: KIDNEY model num: 0KIDNEYtissue: KIDNEY cancer: Renal Clear Cell Carcinoma (CCRCC) model num: 6KIDNEYtissue: KIDNEY cancer: Renal Cell Carcinoma (RCC) model num: 1PROSTATtissue: PROSTAT cancer: PROSTATE model num: 0PROSTATEtissue: PROSTATE cancer: Prostate Cancer model num: 1THYROItissue: THYROI cancer: THYROID model num: 0THYROIDtissue: THYROID cancer: Thyroid Cancer model num: 3SOFT_TISSUtissue: SOFT_TISSU cancer: SOFT_TISSUE model num: 0SOFT_TISSUEtissue: SOFT_TISSUE cancer: Sarcoma, NOS (SARCNOS) model num: 1SOFT_TISSUEtissue: SOFT_TISSUE cancer: Soft Tissue Sarcoma model num: 6

Drug-gene pathway enrichments

Drug-gene GO enrichments

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
3845 KRAS 2
2475 MTOR 5
5241 PGR 1
4771 NF2 4
Showing 1 to 4 of 31 rows rows per page

Gene in drug-gene network: Network Plot

DasatnibDasatnibCHIR-99021CHIR-99021austocystin.Daustocystin.DRO-3306RO-3306SERPINE1SERPINE1selumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorsnavitoclaxnavitoclaxBRD63610BRD63610triacsin Ctriacsin Ctankyrase inhibitorstankyrase inhibitorsitraconazoleitraconazoleGW-843682XGW-843682XSB225002SB225002SepantroniumSepantroniumNPC26NPC26VX-680VX-680kahalalide Fkahalalide FPROCPROCquinoclaminequinoclamineISX-9ISX-9BIX01294BIX01294ABT737ABT737Merck60Merck60BRD6368BRD6368leucascandrolide Aleucascandrolide AavrainvillamideavrainvillamidepiperlonguminepiperlongumineBRD7137BRD7137PAC-1PAC-1PDGFRBPDGFRBPP-30PP-30kinetin ribosidekinetin ribosideSN-38SN-38NeratinibNeratinibParthenolideParthenolideML 210ML 210AZD-1775AZD-1775ML162ML162ceruleninceruleninAACOCF3AACOCF3GMX1778GMX1778Tyrphostin AG 1478Tyrphostin AG 1478179324-69-7179324-69-7zebularinezebularineGemcitabineGemcitabine(1S,3R)-RSL3(1S,3R)-RSL3curcumincurcuminMYH11MYH11ubistatin Bubistatin BLY 2183240LY 2183240gossypolgossypolBRD4770BRD4770LexibulinLexibulinCHEK2CHEK2QuiflaponQuiflaponmanumycin.Amanumycin.Acytochalasin.Bcytochalasin.BNSC95397NSC95397PRIMA-1PRIMA-1Compound.7d.cisCompound.7d.cisSR-II-138ASR-II-138ABRD4132BRD4132SKI IISKI IINSC23766NSC23766SMR000068650SMR000068650MYCLMYCLcetuximabcetuximabPI3K pathway inhibitors (alone or in combination)PI3K pathway inhibitors (alone or in combination)EverolimusEverolimusisoevodiamineisoevodiamineparbendazoleparbendazoletosedostattosedostatoligomycin.Aoligomycin.AML214ML214triptolidetriptolidePI3K pathway inhibitorsPI3K pathway inhibitorsBYL719 (Alpelisib)BYL719 (Alpelisib)trastuzumab alonetrastuzumab alonePIK3CAPIK3CAPX 12PX 12tipifarnib-P2tipifarnib-P2neopeltolideneopeltolidemTOR inhibitorsmTOR inhibitorsNsc 632839Nsc 632839indisulamindisulamFqi1Fqi1CHM-1CHM-1TSC1TSC1BMS-536924BMS-536924chaetocinchaetocinSirolimusSirolimusTSC2TSC2RITARITAVER 155008VER 155008ChloropentafluorobenzeneChloropentafluorobenzeneTP53BP1TP53BP1serdemetanserdemetanCompound.1541ACompound.1541AnakiterpiosinnakiterpiosinCyanoquinoline, 11Cyanoquinoline, 11FedratinibFedratinibTYRO3TYRO3SCHEMBL13586708SCHEMBL13586708FQI-2FQI-2MTORMTORBMS-754807BMS-754807SYK inhibitorsSYK inhibitorsSCHEMBL2608041SCHEMBL2608041SYKSYKPertuzumabPertuzumablapatinib in HER2-amplifiedlapatinib in HER2-amplifiedDacomitinibDacomitinibAfatnibAfatnibERBB2 TKIsERBB2 TKIschemotherapychemotherapyVorinostat (SAHA)Vorinostat (SAHA)Ado-trastuzumab emtansineAdo-trastuzumab emtansineERBB2ERBB2MEK inhibitorsMEK inhibitors(-)-gallocatechin-3-O-gallate(-)-gallocatechin-3-O-gallatepevonedistatpevonedistatERBB3ERBB3GefitnibGefitnibCHEMBL399379CHEMBL399379ErlotinibErlotinibPanitumumabPanitumumabPD0325901PD0325901NSC141540NSC141540SarcolysinSarcolysinRefametinibRefametinibRegorafenibRegorafenibTrametinibTrametinibKRASKRASSL.0101.1SL.0101.1NU-7441NU-7441X17AAGX17AAGall trans Retinoic Acidall trans Retinoic AcidSB590885SB590885TIGARTIGARMST-312MST-312TamoxifenTamoxifen2,4-dideoxy-DC-45-A22,4-dideoxy-DC-45-A2ABT-751ABT-751YK.4.279YK.4.279pluripotinpluripotinPGRPGRBevacizumabBevacizumabCompound 110Compound 110AR-42AR-42Imatinib MesylateImatinib MesylateFAK inhibitorsFAK inhibitorsPAK inhibitorsPAK inhibitorsNF2NF2XAV 939XAV 939GSK429286AGSK429286AMasitinibMasitinibJNK.Inhibitor.VIIIJNK.Inhibitor.VIIISOX17SOX17ETS1ETS1BX-795BX-795DactolisibDactolisibBI-2536BI-2536OSW-1OSW-1CCNE1CCNE1RAB25RAB25PD-0325901PD-0325901PYGBPYGBVHLVHLEEF2EEF2allosteric AKT inhibitorsallosteric AKT inhibitorsKIN001-102KIN001-102BRAF inhibitorsBRAF inhibitorsGSK2141795 (hydrochloride)GSK2141795 (hydrochloride)AZD5363AZD5363MK-2206MK-2206non-allosteric AKT inhibitorsnon-allosteric AKT inhibitorsVemurafenibVemurafenibnutlin 3nutlin 3AC55649AC55649AKT1AKT1CDK4/6 inhibitorsCDK4/6 inhibitorsPD-0332991PD-0332991UNC0638UNC0638lovastatin acidlovastatin acidCIL41CIL41BRD9876BRD9876erastinerastinCCND1CCND1MotesanibMotesanibNCGC00346967-01NCGC00346967-01NilotinibNilotinibOlaparibOlaparibGW441756XGW441756XBosutinibBosutinibBAZ2BBAZ2BLY3023414LY3023414GSK2636771GSK2636771bistramide Abistramide APARP inhibitorsPARP inhibitorsAZD8186AZD8186GSK690693GSK690693PTENPTENIdarubicinIdarubicinTW-37TW-37CD437CD437EP300EP300tensirolimus plus chemotherapytensirolimus plus chemotherapy

Models in Temsirolimus

Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
EXP(NFKBP65_pS536) protein MCLP BLOOD undefined Temsirolimus sensitivity in vitro
EXP(53BP1) protein MCLP undefined PANCAN Temsirolimus resistance in vitro
EXP(AKT_pT308) protein MCLP undefined PANCAN Temsirolimus resistance in vitro
EXP(CLAUDIN7) protein MCLP undefined PANCAN Temsirolimus sensitivity in vitro
EXP(ECADHERIN) protein MCLP undefined PANCAN Temsirolimus sensitivity in vitro
EXP(EEF2) protein MCLP undefined PANCAN Temsirolimus resistance in vitro
EXP(EGFR_pY1068) protein MCLP undefined PANCAN Temsirolimus sensitivity in vitro
EXP(HER3) protein MCLP undefined PANCAN Temsirolimus sensitivity in vitro
EXP(SYK) protein MCLP undefined PANCAN Temsirolimus sensitivity in vitro
EXP(ETS1) protein MCLP undefined PANCAN Temsirolimus resistance in vitro
Showing 1 to 10 of 62 rows rows per page

​​​​

SITE
DATATYPES
CLASSFICATION
Map

Copyright © 2018 Modellab | All Rights Reserved

Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.